{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:02:39Z","timestamp":1791939759598,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004739","name":"Chinese Academy of Sciences Youth Innovation Promotion Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.actbio.2025.02.037","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:09:46Z","timestamp":1739984986000},"page":"283-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Cationic liposomes as broad-spectrum antidotes for heparin-based anticoagulants"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5449-8029","authenticated-orcid":false,"given":"Jiarui","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4602-6815","authenticated-orcid":false,"given":"Yinlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10294","key":"10.1016\/j.actbio.2025.02.037_bib0001","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(20)32658-1","article-title":"Venous thromboembolism","volume":"398","author":"Khan","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.actbio.2025.02.037_bib0002","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.actbio.2025.02.037_bib0003","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdz111","article-title":"Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants","volume":"30","author":"Ay","year":"2019","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.actbio.2025.02.037_bib0004","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2025.02.037_bib0005","doi-asserted-by":"crossref","first-page":"15006","DOI":"10.1038\/nrdp.2015.6","article-title":"Venous thrombosis","volume":"1","author":"Wolberg","year":"2015","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"3","key":"10.1016\/j.actbio.2025.02.037_bib0006","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/CIRCRESAHA.118.313155","article-title":"Antithrombotic agents","volume":"124","author":"Chan","year":"2019","journal-title":"Circ. Res."},{"issue":"11","key":"10.1016\/j.actbio.2025.02.037_bib0007","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of Cardiovascular Disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"10264","key":"10.1016\/j.actbio.2025.02.037_bib0008","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: evidence and unresolved issues","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.actbio.2025.02.037_bib0009","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIRCULATIONAHA.118.037955","article-title":"Efficacy and safety of Apixaban versus Warfarin in patients with atrial fibrillation and extremes in body weight","volume":"139","author":"Hohnloser","year":"2019","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.actbio.2025.02.037_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/cells11203214","article-title":"Anticoagulants: a short history, their mechanism of action, pharmacology, and indications","volume":"11","author":"Heestermans","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.actbio.2025.02.037_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111561","article-title":"Pharmacological and clinical application of heparin progress: an essential drug for modern medicine","volume":"139","author":"Qiu","year":"2021","journal-title":"Biomed. PharmacOther"},{"issue":"2","key":"10.1016\/j.actbio.2025.02.037_bib0012","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/pharmrev.122.000684","article-title":"Pharmacology of Heparin and related drugs: an update","volume":"75","author":"Hogwood","year":"2023","journal-title":"Pharmacol. Rev."},{"issue":"14","key":"10.1016\/j.actbio.2025.02.037_bib0013","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMcp067264","article-title":"Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients","volume":"356","author":"Francis","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.actbio.2025.02.037_bib0014","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1742-1241.2002.tb11334.x","article-title":"Fondaparinux (Arixtra): a new anticoagulant","volume":"56","author":"Giangrande","year":"2002","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.actbio.2025.02.037_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/10742484221145010","article-title":"Fondaparinux sodium: recent advances in the management of thrombosis","volume":"28","author":"Bauersachs","year":"2023","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.actbio.2025.02.037_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2013.06.007","article-title":"Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer","volume":"88","author":"Walenga","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"10","key":"10.1016\/j.actbio.2025.02.037_bib0017","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1182\/blood-2007-10-120543","article-title":"Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents","volume":"111","author":"Crowther","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.actbio.2025.02.037_bib0018","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood-2018-06-820746","article-title":"Treatment of bleeding complications in patients on anticoagulant therapy","volume":"133","author":"Piran","year":"2019","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.actbio.2025.02.037_bib0019","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.actbio.2025.02.037_bib0020","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.actbio.2025.02.037_bib0021","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMa"},{"issue":"3","key":"10.1016\/j.actbio.2025.02.037_bib0022","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamasurg.2015.3592","article-title":"Use of protamine for anticoagulation during carotid endarterectomy: a meta-analysis","volume":"151","author":"Newhall","year":"2016","journal-title":"JAMa Surg."},{"issue":"7","key":"10.1016\/j.actbio.2025.02.037_bib0023","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jtha.2023.04.005","article-title":"What's fishy about protamine? Clinical use, adverse reactions, and potential alternatives","volume":"21","author":"Levy","year":"2023","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.actbio.2025.02.037_bib0024","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4103\/aca.aca_117_23","article-title":"Protamine and heparin interactions: a narrative review","volume":"27","author":"Crivellari","year":"2024","journal-title":"Ann. Card. Anaesth."},{"issue":"1","key":"10.1016\/j.actbio.2025.02.037_bib0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1051\/ject\/202052063","article-title":"Are we able to dose protamine accurately yet? A review of the protamine conundrum","volume":"52","author":"Hecht","year":"2020","journal-title":"J. Extra Corpor. Technol."},{"issue":"2","key":"10.1016\/j.actbio.2025.02.037_bib0026","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12630-022-02364-4","article-title":"Minimum protamine dose required to neutralize heparin in cardiac surgery: a single-centre, prospective, observational cohort study","volume":"70","author":"Taneja","year":"2023","journal-title":"Can. J. Anaesth."},{"issue":"5","key":"10.1016\/j.actbio.2025.02.037_bib0027","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.bja.2018.01.023","article-title":"Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review","volume":"120","author":"Boer","year":"2018","journal-title":"Br. J. Anaesth."},{"issue":"15","key":"10.1016\/j.actbio.2025.02.037_bib0028","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2012-11-469130","article-title":"High incidence of antibodies to protamine and protamine\/heparin complexes in patients undergoing cardiopulmonary bypass","volume":"121","author":"Lee","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.actbio.2025.02.037_bib0029","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1053\/j.jvca.2024.08.024","article-title":"Assessment of perioperative protamine reactions in patients with fish allergies: a retrospective observational study","volume":"38","author":"Youssef","year":"2024","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"10.1016\/j.actbio.2025.02.037_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.avsg.2020.06.016","article-title":"Protamine induced anaphylactic shock after peripheral vascular surgery","volume":"69","author":"Peeters","year":"2020","journal-title":"Ann. Vasc. Surg."},{"issue":"10","key":"10.1016\/j.actbio.2025.02.037_bib0031","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1039\/C5SC01208B","article-title":"Small molecule antagonists of cell-surface heparan sulfate and heparin-protein interactions","volume":"6","author":"Weiss","year":"2015","journal-title":"Chem. Sci."},{"issue":"4","key":"10.1016\/j.actbio.2025.02.037_bib0032","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/blood-2003-07-2334","article-title":"Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo","volume":"103","author":"Schick","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.actbio.2025.02.037_bib0033","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1182\/blood-2016-10-747915","article-title":"Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA","volume":"129","author":"Kalathottukaren","year":"2017","journal-title":"Blood"},{"issue":"260","key":"10.1016\/j.actbio.2025.02.037_bib0034","doi-asserted-by":"crossref","first-page":"260ra150","DOI":"10.1126\/scitranslmed.3009427","article-title":"Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants","volume":"6","author":"Shenoi","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"22","key":"10.1016\/j.actbio.2025.02.037_bib0035","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2014-05-577932","article-title":"Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis","volume":"124","author":"Travers","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.actbio.2025.02.037_bib0036","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1039\/C7MD00527J","article-title":"Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics","volume":"9","author":"Consoli","year":"2018","journal-title":"Medchemcomm."},{"issue":"10","key":"10.1016\/j.actbio.2025.02.037_bib0037","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/eurheartj\/ehab706","article-title":"Ciraparantag as a potential universal anticoagulant reversal agent","volume":"43","author":"Chan","year":"2022","journal-title":"Eur. Heart. J."},{"issue":"10","key":"10.1016\/j.actbio.2025.02.037_bib0038","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40264-020-00962-z","article-title":"Neuroprotective cationic arginine-rich peptides (CARPs): an assessment of their clinical safety","volume":"43","author":"Edwards","year":"2020","journal-title":"Drug Saf."},{"issue":"3","key":"10.1016\/j.actbio.2025.02.037_bib0039","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1021\/bc4005156","article-title":"Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo","volume":"25","author":"Liu","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.actbio.2025.02.037_bib0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jconrel.2014.05.056","article-title":"Low molecular weight protamine (LMWP): a nontoxic protamine substitute and an effective cell-penetrating peptide","volume":"193","author":"He","year":"2014","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2025.02.037_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.744657","article-title":"Micelles based on lysine, histidine, or arginine: designing structures for enhanced drug delivery","volume":"9","author":"Xie","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"31","key":"10.1016\/j.actbio.2025.02.037_bib0042","doi-asserted-by":"crossref","first-page":"18018","DOI":"10.1039\/C9RA02461A","article-title":"Lysine-based dendrimer with double arginine residues","volume":"9","author":"Sheveleva","year":"2019","journal-title":"RSC. Adv."},{"issue":"7","key":"10.1016\/j.actbio.2025.02.037_bib0043","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1039\/D2NH00070A","article-title":"Engineered extracellular vesicles as intelligent nanosystems for next-generation nanomedicine","volume":"7","author":"Fan","year":"2022","journal-title":"Nanoscale Horiz."},{"issue":"6","key":"10.1016\/j.actbio.2025.02.037_bib0044","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201901541","article-title":"Recent advances in nanotheranostics for treat-to-target of rheumatoid arthritis","volume":"9","author":"Wang","year":"2020","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.actbio.2025.02.037_bib0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-0716-2954-3_4","article-title":"Thin-film hydration followed by extrusion method for liposome preparation","volume":"2622","author":"Zhang","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.actbio.2025.02.037_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113851","article-title":"Liposome composition in drug delivery design, synthesis, characterization, and clinical application","volume":"176","author":"Large","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.actbio.2025.02.037_bib0047","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.emc.2018.04.014","article-title":"Anticoagulation reversal","volume":"36","author":"Simon","year":"2018","journal-title":"Emerg. Med. Clin. North Am."},{"key":"10.1016\/j.actbio.2025.02.037_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"23","key":"10.1016\/j.actbio.2025.02.037_bib0049","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202200549","article-title":"Porous polymers as universal reversal agents for Heparin anticoagulants through an inclusion-sequestration mechanism","volume":"34","author":"Lin","year":"2022","journal-title":"Adv. Mater."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174270612500131X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174270612500131X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T03:19:39Z","timestamp":1741922379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S174270612500131X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":49,"alternative-id":["S174270612500131X"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2025.02.037","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cationic liposomes as broad-spectrum antidotes for heparin-based anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2025.02.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acta Materialia Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}